How can the Specific Requirements for Sterile Products be Taken into Account in the Quality Management System?

06.04.2026

Question of the Week

The Pharmaceutical Quality System (PQS) of a sterile manufacturer should cover the specific requirements of sterile products and thus ensure that the risk of particulate and microbial contamination (including endotoxins) is minimized.

[GMP Compliance Adviser, Chapter 12.C]

Would you like to discover more?

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business.

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

How can the Specific Requirements for Sterile Products be Taken into Account in the Quality Management System?

06.04.2026

Question of the Week

How can the Specific Requirements for Sterile Products be Taken into Account in the Quality Management System?

Here's the answer:

GMP Meets Radiation Protection – How Do They Fit Together?

06.04.2026

LOGFILE Feature

GMP Meets Radiation Protection – How Do They Fit Together?

The manufacture of radiopharmaceuticals requires simultaneous compliance with the EU GMP Guide and radiation protection regulations, which can lead to conflicting objectives between product safety and personal protection. Technical solutions such as negative pressure systems and lead-lined cells, as well as early consultation with the authorities, are crucial for implementation that complies with both GMP and radiation protection requirements.

02.04.2026

News

ICH: Updated Q9(R1) Briefing Pack

The ICH has fully revised the Q9(R1) Briefing Pack (March/April 2026) to align with the updated ICH Q9 guideline.

27.03.2026

News

EMA: New Plans for the EU GMP Guide

EMA published the GMDP Inspectors Working Group’s new 2026-2028 work plan and its 2025 annual report.

EMA: Pharmaceutical Quality System (PQS) Effectiveness Pilot Project

27.03.2026

News

EMA: Pharmaceutical Quality System (PQS) Effectiveness Pilot Project

EMA launched a pilot under which EEA GMP inspectors will assess how sites demonstrate the effectiveness of their pharmaceutical quality system for risk-based change management, and whether the EEA GMP certificate could serve as the main evidence of this effectiveness.

EMA: Updated Guideline on Active Substance Chemistry

27.03.2026

News

EMA: Updated Guideline on Active Substance Chemistry

The EMA has updated guidance on the information required for the manufacture and control of active substances used in medicinal products, with a 1 September 2026 date of application.